Moshe Chaim Ornstein

2.4k total citations
133 papers, 1.5k citations indexed

About

Moshe Chaim Ornstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Moshe Chaim Ornstein has authored 133 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Pulmonary and Respiratory Medicine, 79 papers in Oncology and 33 papers in Surgery. Recurrent topics in Moshe Chaim Ornstein's work include Renal cell carcinoma treatment (79 papers), Cancer Immunotherapy and Biomarkers (54 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Moshe Chaim Ornstein is often cited by papers focused on Renal cell carcinoma treatment (79 papers), Cancer Immunotherapy and Biomarkers (54 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Moshe Chaim Ornstein collaborates with scholars based in United States, United Kingdom and South Korea. Moshe Chaim Ornstein's co-authors include Brian I. Rini, Jorge A. García, Timothy D. Gilligan, Jennifer Tran, Petros Grivas, Kimberly D Allman, Laura S. Wood, Pedro C. Barata, Allison Martin and Vadim S. Koshkin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Moshe Chaim Ornstein

121 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Moshe Chaim Ornstein United States	21	913	723	486	386	356	133	1.5k
Sabeen Mekan United States	14	439 0.5×	479 0.7×	274 0.6×	146 0.4×	102 0.3×	52	838
Carole Hélissey France	14	558 0.6×	527 0.7×	163 0.3×	197 0.5×	126 0.4×	81	1.1k
Frédèric Selle France	24	599 0.7×	1.4k 1.9×	254 0.5×	238 0.6×	940 2.6×	127	2.4k
Daniele Raggi Italy	26	540 0.6×	596 0.8×	352 0.7×	125 0.3×	1.5k 4.3×	177	2.0k
Claire F. Friedman United States	21	463 0.5×	1.6k 2.2×	280 0.6×	171 0.4×	369 1.0×	80	2.1k
Mathew M. Augustine United States	19	515 0.6×	1.2k 1.7×	133 0.3×	181 0.5×	509 1.4×	45	1.8k
Tsunenori Kondo Japan	20	850 0.9×	349 0.5×	411 0.8×	131 0.3×	699 2.0×	134	1.5k
Do Hyoung Lim South Korea	15	642 0.7×	725 1.0×	202 0.4×	126 0.3×	365 1.0×	39	1.1k
Urban Scheuring Germany	19	675 0.7×	579 0.8×	508 1.0×	433 1.1×	53 0.1×	40	1.9k
Avi B. Markowitz United States	16	383 0.4×	561 0.8×	245 0.5×	89 0.2×	377 1.1×	35	1.1k

Countries citing papers authored by Moshe Chaim Ornstein

Since Specialization

Citations

This map shows the geographic impact of Moshe Chaim Ornstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moshe Chaim Ornstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moshe Chaim Ornstein more than expected).

Fields of papers citing papers by Moshe Chaim Ornstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moshe Chaim Ornstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moshe Chaim Ornstein. The network helps show where Moshe Chaim Ornstein may publish in the future.

Co-authorship network of co-authors of Moshe Chaim Ornstein

This figure shows the co-authorship network connecting the top 25 collaborators of Moshe Chaim Ornstein. A scholar is included among the top collaborators of Moshe Chaim Ornstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moshe Chaim Ornstein. Moshe Chaim Ornstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choueiri, Toni K., Jae‐Lyun Lee, Jaime R. Merchan, et al.. (2025). Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.. Journal of Clinical Oncology. 43(5_suppl). 441–441.

Dizman, Nazlı, Andrea Knežević, Reza Alaghehbandan, et al.. (2024). A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4512–4512. 3 indexed citations

Ornstein, Moshe Chaim, Wei Wei, C. Marcela Díaz‐Montero, et al.. (2024). Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clinical Genitourinary Cancer. 22(6). 102181–102181.

Ornstein, Moshe Chaim, Shilpa Gupta, Jesse K. McKenney, et al.. (2024). A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC). Urologic Oncology Seminars and Original Investigations. 42. S31–S31.

McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13. 1 indexed citations

Makarov, Vladimir, Scott J. Dawsey, Paul G. Pavicic, et al.. (2024). Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.. Journal of Clinical Oncology. 42(4_suppl). 670–670. 1 indexed citations

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

Ornstein, Moshe Chaim, et al.. (2023). Targeting HIF-2 Alpha in Renal Cell Carcinoma. Current Treatment Options in Oncology. 24(9). 1183–1198. 10 indexed citations

Wee, Christopher Eing, Amanda Nizam, Moshe Chaim Ornstein, et al.. (2023). Using sacituzumab govitecan for metastatic urothelial carcinoma after prior treatment with enfortumab vedotin: A single institution experience.. JCO Global Oncology. 9(Supplement_1). 78–78. 2 indexed citations

10.

Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.

11.

Nizam, Amanda, Ryan K. Rader, Alice Tzeng, et al.. (2023). Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events. Clinical Genitourinary Cancer. 22(2). 368–379. 6 indexed citations

12.

Schuster, James, C.A. Reddy, Alok A. Khorana, et al.. (2023). Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 22(2). 92–97. 1 indexed citations

13.

Campbell, Steven C., Moshe Chaim Ornstein, & Nityam Rathi. (2022). Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro. European Urology Open Science. 44. 92–93. 1 indexed citations

14.

Brown, Landon C., Kunal Desai, Wei Wei, et al.. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for ImmunoTherapy of Cancer. 9(9). e003281–e003281. 13 indexed citations

15.

Nizam, Amanda, et al.. (2020). The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer Treatment and Research Communications. 23. 100169–100169. 11 indexed citations

16.

Fallah, Jaleh, C. Marcela Díaz‐Montero, Patricia Rayman, et al.. (2020). Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. Clinical Genitourinary Cancer. 18(6). 500–508. 8 indexed citations

17.

Desai, Kunal, Lisa Rybicki, Amanda Nizam, et al.. (2020). Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N).. Journal of Clinical Oncology. 38(15_suppl). e17094–e17094. 1 indexed citations

18.

Ornstein, Moshe Chaim, Cassandra Calabrese, Laura S. Wood, et al.. (2019). Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 17(3). 177–182. 9 indexed citations

19.

Barata, Pedro C., Alfonso Gómez de Liaño, Prateek Mendiratta, et al.. (2018). Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. Journal of Clinical Oncology. 36(6_suppl). 613–613. 6 indexed citations

20.

Ornstein, Moshe Chaim & Jorge A. García. (2017). Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. PubMed. 1(2). 133–141. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact